Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.
2.

Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Marín MQ, Pérez P, Ljungberg K, Sorzano CÓS, Gómez CE, Liljeström P, Esteban M, García-Arriaza J.

J Virol. 2019 Mar 21;93(7). pii: e00055-19. doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.

PMID:
30674625
3.

Growth and feeding of deep-sea coral Lophelia pertusa from the California margin under simulated ocean acidification conditions.

Gómez CE, Wickes L, Deegan D, Etnoyer PJ, Cordes EE.

PeerJ. 2018 Sep 27;6:e5671. doi: 10.7717/peerj.5671. eCollection 2018.

4.

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.

Perdiguero B, Raman SC, Sánchez-Corzo C, Sorzano COS, Valverde JR, Esteban M, Gómez CE.

Viruses. 2018 Aug 13;10(8). pii: E424. doi: 10.3390/v10080424.

5.

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.

Marín MQ, Pérez P, Gómez CE, Sorzano CÓS, Esteban M, García-Arriaza J.

Viruses. 2018 Aug 8;10(8). pii: E414. doi: 10.3390/v10080414.

6.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, de Quirós JCLB, García F, Plana M; RISVAC02boost study.

PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. eCollection 2018.

7.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.

Saunders KO, Santra S, Parks R, Yates NL, Sutherland LL, Scearce RM, Balachandran H, Bradley T, Goodman D, Eaton A, Stanfield-Oakley SA, Tartaglia J, Phogat S, Pantaleo G, Esteban M, Gomez CE, Perdiguero B, Jacobs B, Kibler K, Korber B, Montefiori DC, Ferrari G, Vandergrift N, Liao HX, Tomaras GD, Haynes BF.

J Virol. 2018 Mar 28;92(8). pii: e02035-17. doi: 10.1128/JVI.02035-17. Print 2018 Apr 15.

8.

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.

Gómez CE, Perdiguero B, Sánchez-Corzo C, Sorzano COS, Esteban M.

Viruses. 2017 Dec 27;10(1). pii: E7. doi: 10.3390/v10010007.

9.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study.

PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. Erratum in: PLoS One. 2018 Apr 10;13(4):e0195915.

10.

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.

Rosás-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobarsí P, Gomez CE, Esteban M, Jímenez JL, García F, Blanco J, Martinez-Picado J, Paredes R, Brander C.

PLoS One. 2017 Sep 27;12(9):e0184929. doi: 10.1371/journal.pone.0184929. eCollection 2017.

11.

Environmental filtering and neutral processes shape octocoral community assembly in the deep sea.

Quattrini AM, Gómez CE, Cordes EE.

Oecologia. 2017 Jan;183(1):221-236. doi: 10.1007/s00442-016-3765-4. Epub 2016 Nov 8.

PMID:
27826800
12.

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.

Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano CÓ, Mothe B, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, López Bernaldo de Quirós JC, Brander C, García F, Esteban M.

PLoS One. 2015 Nov 6;10(11):e0141456. doi: 10.1371/journal.pone.0141456. eCollection 2015.

13.

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

Hulot SL, Korber B, Giorgi EE, Vandergrift N, Saunders KO, Balachandran H, Mach LV, Lifton MA, Pantaleo G, Tartaglia J, Phogat S, Jacobs B, Kibler K, Perdiguero B, Gomez CE, Esteban M, Rosati M, Felber BK, Pavlakis GN, Parks R, Lloyd K, Sutherland L, Scearce R, Letvin NL, Seaman MS, Alam SM, Montefiori D, Liao HX, Haynes BF, Santra S.

J Virol. 2015 Jun;89(12):6462-80. doi: 10.1128/JVI.00383-15. Epub 2015 Apr 8.

14.

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Di Pilato M, Mejías-Pérez E, Zonca M, Perdiguero B, Gómez CE, Trakala M, Nieto J, Nájera JL, Sorzano CO, Combadière C, Pantaleo G, Planelles L, Esteban M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1333-42. doi: 10.1073/pnas.1424341112. Epub 2015 Mar 4.

15.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group.

J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26.

PMID:
25724985
16.

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.

Delaloye J, Filali-Mouhim A, Cameron MJ, Haddad EK, Harari A, Goulet JP, Gomez CE, Perdiguero B, Esteban M, Pantaleo G, Roger T, Sékaly RP, Calandra T.

J Virol. 2015 Apr;89(7):3819-32. doi: 10.1128/JVI.03061-14. Epub 2015 Jan 21.

17.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.

18.

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M.

J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.

19.

Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.

Cáceres A, Perdiguero B, Gómez CE, Cepeda MV, Caelles C, Sorzano CO, Esteban M.

PLoS Pathog. 2013;9(11):e1003719. doi: 10.1371/journal.ppat.1003719. Epub 2013 Nov 14.

20.

Clinical applications of attenuated MVA poxvirus strain.

Gómez CE, Perdiguero B, García-Arriaza J, Esteban M.

Expert Rev Vaccines. 2013 Dec;12(12):1395-416. doi: 10.1586/14760584.2013.845531. Epub 2013 Oct 30. Review.

PMID:
24168097
21.

New vaccinia virus promoter as a potential candidate for future vaccines.

Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sorzano CO, Esteban M.

J Gen Virol. 2013 Dec;94(Pt 12):2771-6. doi: 10.1099/vir.0.057299-0. Epub 2013 Sep 28.

PMID:
24077296
22.

Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.

Perdiguero B, Gómez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2013 Sep 17;8(9):e74831. doi: 10.1371/journal.pone.0074831. eCollection 2013.

23.

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

García-Arriaza J, Arnáez P, Gómez CE, Sorzano CÓ, Esteban M.

PLoS One. 2013 Jun 27;8(6):e66894. doi: 10.1371/journal.pone.0066894. Print 2013.

24.

High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.

Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CÓ, Esteban M.

J Virol. 2013 Jul;87(13):7282-300. doi: 10.1128/JVI.03246-12. Epub 2013 Apr 17.

25.

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Pérez-Jiménez E, Oliveros JC, Esteban M.

J Virol. 2013 Jun;87(12):6955-74. doi: 10.1128/JVI.03013-12. Epub 2013 Apr 17.

26.

Endolymphatic sac tumor and otalgia.

Zarghouni M, Kershen ML, Skaggs L, Bhatki A, Gilbert SC, Gomez CE, Opatowsky MJ.

Proc (Bayl Univ Med Cent). 2013 Apr;26(2):159-60.

27.

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.

Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA.

J Immunol. 2013 Mar 15;190(6):2720-35. doi: 10.4049/jimmunol.1202861. Epub 2013 Feb 6.

28.

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.

29.

Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21. Review.

30.

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.

Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, Esteban M.

PLoS One. 2012;7(6):e38859. doi: 10.1371/journal.pone.0038859. Epub 2012 Jun 8.

31.

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

García-Arriaza J, Arnáez P, Jiménez JL, Gómez CE, Muñoz-Fernández MÁ, Esteban M.

Virus Res. 2012 Aug;167(2):391-6. doi: 10.1016/j.virusres.2012.05.020. Epub 2012 May 30.

PMID:
22659488
32.

Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.

Vijayan A, Gómez CE, Espinosa DA, Goodman AG, Sanchez-Sampedro L, Sorzano CO, Zavala F, Esteban M.

J Immunol. 2012 Jun 15;188(12):6407-17. doi: 10.4049/jimmunol.1102492. Epub 2012 May 21.

33.

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

Gómez CE, Perdiguero B, Jiménez V, Filali-Mouhim A, Ghneim K, Haddad EK, Quakkelaar ED, Delaloye J, Harari A, Roger T, Duhen T, Sékaly RP, Melief CJ, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M.

PLoS One. 2012;7(4):e35485. doi: 10.1371/journal.pone.0035485. Epub 2012 Apr 19. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/44b8f849-7885-4ad0-8fc9-b252c9ee1790. Dunhen, Thomas [corrected to Duhen, Thomas]. PLoS One. 2012;7(5): doi/10.1371/annotation/09c18b10-8433-4d64-be1c-61e578cc088b. Quakkerlaar [corrected to Quakkelaar, Esther D]..

34.

Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M.

J Virol. 2012 May;86(9):5026-38. doi: 10.1128/JVI.06684-11. Epub 2012 Mar 14.

35.

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.

Falivene J, Del Médico Zajac MP, Pascutti MF, Rodríguez AM, Maeto C, Perdiguero B, Gómez CE, Esteban M, Calamante G, Gherardi MM.

PLoS One. 2012;7(2):e32220. doi: 10.1371/journal.pone.0032220. Epub 2012 Feb 22.

36.

Improved NYVAC-based vaccine vectors.

Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, Sékaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M.

PLoS One. 2011;6(11):e25674. doi: 10.1371/journal.pone.0025674. Epub 2011 Nov 9.

37.

A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.

Goodman AG, Heinen PP, Guerra S, Vijayan A, Sorzano CO, Gomez CE, Esteban M.

PLoS One. 2011;6(10):e25938. doi: 10.1371/journal.pone.0025938. Epub 2011 Oct 5.

38.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

39.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
40.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.

J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24.

41.

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.

Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, Piqué N, Gil C, Gatell JM, Esteban M, Gallart T.

PLoS One. 2011;6(5):e19644. doi: 10.1371/journal.pone.0019644. Epub 2011 May 18.

42.

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.

Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban M, Park CG, Trumpfheller C, Keler T, Pantaleo G, Steinman RM, Seder R.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7131-6. doi: 10.1073/pnas.1103869108. Epub 2011 Apr 5.

43.

MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M.

Curr Gene Ther. 2011 Jun;11(3):189-217. Review.

PMID:
21453284
44.

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet JP, Loof NM, Ossendorp F, Perdiguero B, Heinen P, Gomez CE, Kibler KV, Koelle DM, Sékaly RP, Sallusto F, Lanzavecchia A, Pantaleo G, Esteban M, Tartaglia J, Jacobs BL, Melief CJ.

PLoS One. 2011 Feb 15;6(2):e16819. doi: 10.1371/journal.pone.0016819.

45.

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.

Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M.

Vaccine. 2011 Feb 4;29(7):1504-13. doi: 10.1016/j.vaccine.2010.12.016. Epub 2010 Dec 21.

PMID:
21182993
46.

Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys.

Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR.

J Immunol. 2010 Dec 1;185(11):7097-106. doi: 10.4049/jimmunol.1002751. Epub 2010 Nov 1.

47.

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M.

PLoS One. 2010 Aug 24;5(8):e12395. doi: 10.1371/journal.pone.0012395.

48.

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M.

PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406.

49.

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Guerra S, González JM, Climent N, Reyburn H, López-Fernández LA, Nájera JL, Gómez CE, García F, Gatell JM, Gallart T, Esteban M.

J Virol. 2010 Aug;84(16):8141-52. doi: 10.1128/JVI.00749-10. Epub 2010 Jun 9.

50.

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.

Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T.

PLoS Pathog. 2009 Jun;5(6):e1000480. doi: 10.1371/journal.ppat.1000480. Epub 2009 Jun 19.

Supplemental Content

Loading ...
Support Center